title: Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol.
abstract: OBJECTIVE
  To test the feasibility and efficacy of an approach that foregoes the routine use of ultrasound for the determination of eligibility for medical termination of pregnancy.
  
  
  METHODS
  Prospective trial.
  
  
  METHODS
  Ten termination of pregnancy clinics in the USA.
  
  
  METHODS
  A total of 4484 women seeking termination of pregnancy with mifepristone-misoprostol.
  
  
  METHODS
  Women provided estimates of the date of their last menstrual period and underwent pelvic bimanual and ultrasound examinations. We compared estimates of gestational age using these three methods.
  
  
  METHODS
  Proportion of women of ≤9 weeks' gestation by woman or provider estimate, but >9 weeks' gestation by ultrasound.
  
  
  RESULTS
  The reliance on women's report of their last menstrual period together with physical examination to determine their eligibility for termination of pregnancy with mifepristone-misoprostol would result in few women (63/4008 or 1.6%) accepted for treatment outside the current limits of standard mifepristone-misoprostol regimens used for early termination of pregnancy (i.e. ≤63 days' gestation on ultrasound).
  
  
  CONCLUSIONS
  Last menstrual period and physical examination alone, without the routine use of ultrasound, are highly effective for the determination of women's eligibility for early termination of pregnancy with mifepristone-misoprostol.
authors.affiliation: Gynuity Health Projects, New York, NY 10010, USA. hbracken@gynuity.org
authors.forename: H
authors.initials: H
authors.lastname: Bracken
authors.forename: W
authors.initials: W
authors.lastname: Clark
authors.forename: E S
authors.initials: ES
authors.lastname: Lichtenberg
authors.forename: S M
authors.initials: SM
authors.lastname: Schweikert
authors.forename: J
authors.initials: J
authors.lastname: Tanenhaus
authors.forename: A
authors.initials: A
authors.lastname: Barajas
authors.forename: L
authors.initials: L
authors.lastname: Alpert
authors.forename: B
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000379:methods*; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage*; D016595:Misoprostol / Q000008:administration & dosage*; D010808:Physical Examination; D011247:Pregnancy; D011446:Prospective Studies; D012646:Self Administration; D016216:Ultrasonography, Prenatal
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D015735:Mifepristone